First and Only FDA Approved Drug for Controlling Pain in Cattle
MADISON, N.J., January 31, 2018 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, today introduced Banamine® Transdermal (flunixin transdermal solution) – the first and only U.S. Food & Drug Administration (FDA) approved product for pain control in a food producing animal. It is approved for the control of pain associated with foot rot and fever associated with bovine respiratory disease (BRD). Applied as a pour-on, BANAMINE TRANSDERMAL is easy to administer for pain and fever management.
“BANAMINE TRANSDERMAL is a breakthrough innovation with its patented delivery,” said Scott Bormann, vice president, North America commercial operations for Merck Animal Health. “It is the first and only non-steroidal, anti-inﬂammatory (NSAID) cattle product available as a pour-on, and the latest example of Merck Animal Health’s commitment to improve animal health and well-being, and provide animal caregiver solutions that help deliver a safe, sustainable food supply.”
The pour-on application eliminates the time-consuming and stressful treatment process associated with intravenous (IV) administration, which is the administration route of previous NSAIDs.
“Studies show that a single dose of BANAMINE TRANSDERMAL is absorbed into the bloodstream within minutes and has long duration of activity at the site of inflammation,” said Scott Nordstrom, D.V.M., associate director, scientific marketing affairs, Merck Animal Health. “This gives cattle the best opportunity to recover quickly and return to productivity.”
In field studies at four U.S. locations involving animals diagnosed with BRD, 58.3 percent of cattle treated with BANAMINE TRANSDERMAL had at least a 2-degree F drop in temperature within six hours of treatment compared to 6.1 percent for the placebo group. Significant results also were seen in two studies around pain associated with foot rot, which showed that 93.3 percent to 100 percent of cattle treated with BANAMINE TRANSDERMAL had improved lameness scores compared to 6.7 percent and 53.3 percent for the placebo groups.
“Veterinarians and producers are increasingly addressing the relationship between animal well-being and lost performance,” Dr. Nordstrom pointed out. “Pain mitigation in animals also is a growing goal across the food chain. Fever and pain can cause cattle to stop eating and drinking. BANAMINE TRANSDERMAL can help cattle feel better for a healthy and productive outcome.”
BANAMINE TRANSDERMAL is a prescription product that meets the best management practices outlined in the industry’s Beef Quality Assurance program. The pour-on application eliminates injection-site lesions within the carcass at marketing and reduces risk of residues, resulting in a higher-value end product.
The pre-calibrated packaging and red-colored solution help ensure the correct dose is given every time. The unique bottle design makes it simple to apply topically on dry skin in a narrow strip down the animal’s midline from the withers to the tail head.
To learn more about BANAMINE TRANSDERMAL, visit BanamineTD.com or contact your veterinarian.
Important Safety Information:
NOT FOR HUMAN USE. KEEP OUT OF REACH OF CHILDREN. Only for topical use in beef and dairy cattle. Do not use Banamine Transdermal pour-on within 48 hours of expected parturition. Do not use in animals showing hypersensitivity to flunixin meglumine. Cattle must not be slaughtered for human consumption within eight days of the last treatment. Not for use in female dairy cattle 20 months of age or older, including dry dairy cows; use in these cattle may cause drug residues in milk and/or in calves born to these cows or heifers. Not for use in suckling beef calves, dairy calves, and veal calves. A withdrawal period has not been established for this product in pre-ruminating calves. Not for use in dairy or beef bulls intended for breeding because reproductive safety has not been evaluated.
BANAMINE® is a registered trademark of Intervet Inc.
About Merck Animal Health
For more than a century, Merck, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Merck Animal Health, known as MSD Animal Health outside the United States and Canada, is the global animal health business unit of Merck. Through its commitment to the Science of Healthier Animals™, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com or connect with us on LinkedIn, Facebook and Twitter at @MerckAH.
Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate
fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to
accurately predict future market conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk; dependence on the effectiveness of the
company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking
statements can be found in the company’s 2014 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).